NL-OMON42997已完成不适用
Assessment of safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of GLPG2451 and of the combination of GLPG2451 and GLPG2222 in healthy female subjects. - GLPG2451 SAD/MAD Study.
Galapagos SAS0 个研究点目标入组 56 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy sterilized women or healthy postmenopausal women
- •18 - 65 years, inclusive
- •BMI 18.0 - 30.0 kg/m2
- •non-smoking
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
Assessment of safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of the combination of GLPG2451 and GLPG2222, with or without GLPG2737, in adult subjects with cystic fibrosisgenetic diseasethick mucus disease10083624NL-OMON46421Galapagos NV6
已完成
不适用
Pharmacokinetics and safety of DA-6034KCT0000793Dong-A Pharm67
已完成
不适用
EVALUATION OF SAFETY, TOLERABILITY AND PHARMACOKINETIC CHARACTERISTICS OF MULTIPLE-ASCENDING DOSES OF CG400549 IN HEALTHY VOLUNTEERSMRSA10004018NL-OMON34490Crystal Genomics24
已完成
不适用
Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of topically applied NT-077 (tiotropium bromide) in healthy volunteers.hyperhydrosisprimary hyperhidrosis is a not well-delineated conditionexcessive sweat productionNL-OMON50872otoxins Holding B.V.4
进行中（未招募）
不适用
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer'sDisease or Mild Alzheimer's DiseaseEUCTR2011-005217-37-ITELI LILLY AND COMPANY260